Pharmacological principles of antibiotic prescription in the critically ill

被引:81
作者
Pinder, M
Bellomo, R
Lipman, J
机构
[1] Royal Brisbane Hosp, Dept Intens Care, Brisbane, Qld 4029, Australia
[2] Intens Care Unit, Perth, WA, Australia
[3] Austin & Repatriat Med Ctr, Melbourne, Vic, Australia
关键词
antibiotics; intensive care unit; haemofiltration; acute renal failure; pharmacokinetics; pharmacodynamics;
D O I
10.1177/0310057X0203000203
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The goal of antimicrobial prescription is to achieve effective drug concentrations. Standard antimicrobial (losing regimens are based on research performed often decades ago and for the most part with patients who were not critically, ill. More recent insights into antibiotic activity (e.g. the importance of high peak/MIC ratios for aminoglycosides and time above MIC for beta-lactam antibiotics), drug pharmacokinetics (e.g. increased volume of distribution and altered clearances) and the pathogenesis of sepsis (e.g. third space losses and altered creatinine clearances have made re-evaluation of dosing regimens necessary for the critically ill. The inflammatory, response associated with sepsis results in a rapid decrease in serum albumin levels, large fluid shifts and third space losses, initially, with a high cardiac output. In turn these changes result in increased creatinine clearance and increased renal drug clearance. Unless these effects are offset by ensuing renal and/or hepatic impairment, with subsequent drug accumulation, antibiotic levels may, be too low for optimal efficacy. The institution of continuous renal replacement therapy separately, affects antibiotic clearances, and therefore dosing, even further. This article reviews relevant literature and offers principles for more effective and appropriate antibiotic dosing in the critically, ill, based oil the pharmacokinetic and pharmacodynamic principles of the main antibiotic groups (aminoglyosides, glycopeptides, beta-lactams, carbapenems and quinolones) and knowledge of the pathophysiology, of the inflammatory response syndrome. Finally, it also provides sonic guidance oil the basic principles of drug prescription for patients receiving continuous renal replacement therapy.
引用
收藏
页码:134 / 144
页数:11
相关论文
共 110 条
[21]   COMPARATIVE SERUM BACTERICIDAL ACTIVITIES OF 3 DOSES OF CIPROFLOXACIN ADMINISTERED INTRAVENOUSLY [J].
DAN, M ;
POCH, F ;
QUASSEM, C ;
KITZES, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :837-841
[22]   VARIABILITY IN AMINOGLYCOSIDE PHARMACOKINETICS IN CRITICALLY ILL SURGICAL PATIENTS [J].
DASTA, JF ;
ARMSTRONG, DK .
CRITICAL CARE MEDICINE, 1988, 16 (04) :327-330
[23]  
DAVIES J, 2000, INTENS CARE MED, V26, pS269
[24]   Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection [J].
Di Filippo, A ;
De Gaudio, AR ;
Novelli, A ;
Paternostro, E ;
Pelagatti, C ;
Livi, P ;
Novelli, GP .
CHEMOTHERAPY, 1998, 44 (01) :63-68
[25]   THE SELECTION OF APPROPRIATE DOSAGES FOR INTRAVENOUS CIPROFLOXACIN [J].
ECHOLS, RM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (05) :783-787
[26]   CONDITIONS FOR THE EMERGENCE OF RESISTANCE TO CEFPIROME AND CEFTAZIDIME IN EXPERIMENTAL ENDOCARDITIS DUE TO PSEUDOMONAS-AERUGINOSA [J].
FANTIN, B ;
FARINOTTI, R ;
THABAUT, A ;
CARBON, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (03) :563-569
[27]   Effectiveness and safety of once-daily aminoglycosides: A meta-analysis [J].
FerriolsLisart, R ;
AlosAlminana, M .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (10) :1141-1150
[28]   TREATMENT OF SEVERE PNEUMONIA IN HOSPITALIZED-PATIENTS - RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING INTRAVENOUS CIPROFLOXACIN WITH IMIPENEM-CILASTATIN [J].
FINK, MP ;
SNYDMAN, DR ;
NIEDERMAN, MS ;
LEEPER, KV ;
JOHNSON, RH ;
HEARD, SO ;
WUNDERINK, RG ;
CALDWELL, JW ;
SCHENTAG, JJ ;
SIAMI, GA ;
ZAMECK, RL ;
HAVERSTOCK, DC ;
REINHART, HH ;
ECHOLS, RM ;
HELSMOORTEL, C ;
SOJASTRZEPA, D ;
SCHWAITZBERG, S ;
BAREFOOT, L ;
FEIN, AM ;
FEINSILVER, SH ;
ILOWITE, JS ;
CLARE, N ;
SCHULMAN, D ;
JONES, CB ;
GRIFFIN, RI ;
WROBEL, CW ;
BALLOW, CH ;
AMSDEN, G ;
MITCHELL, P ;
BESS, T ;
WILKINS, W ;
BROWN, RB ;
MCGEE, W ;
SAFFORD, MJ ;
LEVINE, DP ;
LERNER, SA ;
KRUSE, JA ;
BANDER, JJ ;
MCNEIL, P ;
MUNKARAH, M ;
SUMMER, WR ;
DEBOISBLANC, B ;
LEVISON, ME ;
KORZENIOWSKI, O ;
SIGLER, A ;
BALDASSARRE, J ;
WALSH, P ;
SAMEL, C ;
SESSLER, CN ;
POLK, RE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (03) :547-557
[29]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[30]   PHARMACOLOGIC FACTORS ASSOCIATED WITH GENTAMICIN NEPHROTOXICITY IN RABBITS [J].
FRAME, PT ;
PHAIR, JP ;
WATANAKUNAKORN, C ;
BANNISTER, TWP .
JOURNAL OF INFECTIOUS DISEASES, 1977, 135 (06) :952-956